omniture
logo
Search
南京驯鹿医疗技术有限公司
Media Room

Latest News

rss

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

PHILADELPHIA and SAN JOSE, Calif. and NANJING and SHANGHAI, China, Oct. 11, 2022 /PRNewswire/ -- IA...

2022-10-11 19:00 1880
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA

SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 19, 2022 /PRNewswire/ -- IASO Biotherapeutics (...

2022-08-19 18:41 1968

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ...

2022-06-02 20:08 3327

IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

SAN JOSE, Calif., NANJING, China and SHANGHAI, May 28, 2022 /PRNewswire/ -- IASO Biotherapeutics (I...

2022-05-28 19:33 5169

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent

NANJING, China and SHANGHAI and SAN JOSE, Calif., Feb. 13, 2022 /PRNewswire/ -- IASO Biotherapeutic...

2022-02-14 08:25 2513

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China andSHANGHAI, Ja...

2022-01-11 05:30 2708

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics (...

2021-12-13 12:14 2218

IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA

SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- IASO Biotherapeutics (...

2021-11-26 11:05 1756

IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021

SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- IASO Biotherapeutics("...

2021-11-10 21:30 1638

IASO Biotheraputics Completes Enrollment of First Patient in CT120's Phase I/II Registrational Clinical Trial

SAN JOSE, Calif. and SHANGHAI and NANJING, China, Nov. 9, 2021 /PRNewswire/ --  IASO Biotherapeutics...

2021-11-09 21:30 1282
12